RxDoctor Payments DataLook up a doctor →

Michael Lillestol, MD

Internal Medicine · Fargo, NDNPI 1669427688

Payments from drug & device makers

$22,524,355in general payments, 2019–2025

Across 3,311 payments — averaging $6802.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$8.9M
  • Pfizer$5.5M
  • Novartis$2.5M
  • AstraZeneca$1.6M
  • Amgen$1.3M
  • Modernatx, Inc.$832K
  • plus $1.9M from 40 others
$110,491in research payments, 2019–2025

Across 35 payments — averaging $3156.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$110K

What the payments were for

  • Consulting fees$7,15039%
  • Travel & lodging$8,56246%
  • Food & beverage$2,73515%
  • Education$120%
  • Gifts$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$22,524,355 in reported general payments places this provider in the 95th percentile of 159 internal medicine providers in North Dakota.

See all internal medicine providers in North Dakota

Medicare billing

Part B allowed, 2024
$109,245
Medicare patients
559
Services billed
3,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide106$138,628
EliquisApixaban71$56,133
XareltoRivaroxaban39$29,299
JardianceEmpagliflozin31$25,866
MounjaroTirzepatide21$25,540
ProliaDenosumab14$23,835
EntrestoSacubitril/Valsartan29$17,830
Repatha SureclickEvolocumab16$11,030
Ezetimibe165$4,610
Rosuvastatin Calcium314$3,830
Metoprolol Succinate118$2,808
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,700
Arnuity ElliptaFluticasone Furoate12$2,507
Atorvastatin Calcium191$2,186
Losartan Potassium198$2,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$51$138,628106 claims
PfizerEliquis$5,475,200$56,13371 claims
Boehringer IngelheimJardiance$101,036$25,86631 claims
AmgenProlia$1,327,320$23,83514 claims
NovartisEntresto$2,508,908$17,83029 claims
GSKArnuity Ellipta$16,108$2,50712 claims
AbbVieSynthroid$56,990$1,54716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 159 internal medicine providers in North Dakota.

Other internal medicine in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →